Tarsus Pharmaceuticals (TARS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is TARS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Commonwealth Equity Services LLC reduced its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 11.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commi…

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:…

Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a…

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript…

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.…

Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product …

The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive tr…

Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and high-reward l…

IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its th…

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served…

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to $685–$705 million, wi…

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual M…

Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based …

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved therapy Strengthe…

Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission…

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthc…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

